Literature DB >> 29168181

Different interleukin-17-secreting Toll-like receptor+ T-cell subsets are associated with disease activity in multiple sclerosis.

Thais B Ferreira1, Joana Hygino2, Ana Cristina Wing3, Taissa M Kasahara1, Priscila M Sacramento1, Solange Camargo4, Fernanda Rueda5, Soniza V Alves-Leon3, Regina Alvarenga3, Claudia Cristina Vasconcelos3, Anshu Agrawal6, Sudhir Gupta6, Cleonice A M Bento1,2,3.   

Abstract

Signalling through Toll-like receptors (TLRs) may play a role in the pathogenesis of autoimmune diseases, such as multiple sclerosis (MS). In the present study, the expression of TLR-2, -4 and -9 was significantly higher on CD4+ and CD8+ T-cells from MS patients compared to healthy individuals. Following in-vitro activation, the proportion of interleukin (IL)-17+ and IL-6+ CD4+ and CD8+ T-cells was higher in the patients. In addition, the proportion of IFN-γ-secreting TLR+ CD8+ T-cells was increased in MS patients. Among different IL-17+ T-cell phenotypes, the proportion of IL-17+ TLR+ CD4+ and CD8+ T-cells producing IFN-γ or IL-6 were positively associated with the number of active brain lesions and neurological disabilities. Interestingly, activation of purified CD4+ and CD8+ T-cells with ligands for TLR-2 (Pam3Csk4), TLR-4 [lipopolysaccharide (LPS)] and TLR-9 [oligodeoxynucleotide (ODN)] directly induced cytokine production in MS patients. Among the pathogen-associated molecular patterns (PAMPs), Pam3Csk4 was more potent than other TLR ligands in inducing the production of all proinflammatory cytokines. Furthermore, IL-6, IFN-γ, IL-17 and granulocyte-macrophage colony-stimulating factor (GM-CSF) levels produced by Pam3Csk4-activated CD4+ cells were directly associated with disease activity. A similar correlation was observed with regard to IL-17 levels released by Pam3Csk4-stimulated CD8+ T-cells and clinical parameters. In conclusion, our data suggest that the expansion of different T helper type 17 (Th17) phenotypes expressing TLR-2, -4 and -9 is associated with MS disease activity, and reveals a preferential ability of TLR-2 ligand in directly inducing the production of cytokines related to brains lesions and neurological disabilities.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Multiple sclerosis; PAMP, Th17/Tc-17 cell subsets; TLR

Mesh:

Substances:

Year:  2017        PMID: 29168181      PMCID: PMC6381308          DOI: 10.1111/imm.12872

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  73 in total

1.  CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells.

Authors:  S Bendigs; U Salzer; G B Lipford; H Wagner; K Heeg
Journal:  Eur J Immunol       Date:  1999-04       Impact factor: 5.532

Review 2.  The critical role of toll-like receptors--From microbial recognition to autoimmunity: A comprehensive review.

Authors:  Maximiliano Javier Jiménez-Dalmaroni; M Eric Gerswhin; Iannis E Adamopoulos
Journal:  Autoimmun Rev       Date:  2015-08-20       Impact factor: 9.754

Review 3.  Adaptor usage and Toll-like receptor signaling specificity.

Authors:  Aisling Dunne; Luke A J O'Neill
Journal:  FEBS Lett       Date:  2005-04-26       Impact factor: 4.124

4.  Association of MBP peptides with Hsp70 in normal appearing human white matter.

Authors:  Brett T Lund; Yervand Chakryan; Nazely Ashikian; Lilit Mnatsakanyan; Carolyn J Bevan; Rodrigo Aguilera; Tim Gallaher; Michael W Jakowec
Journal:  J Neurol Sci       Date:  2006-07-13       Impact factor: 3.181

5.  Evaluation of TLR9 expression on PBMCs and CpG ODN-TLR9 ligation on IFN-α production in SLE patients.

Authors:  Sahar Mortezagholi; Zohreh Babaloo; Parisa Rahimzadeh; Haideh Namdari; Mojgan Ghaedi; Farhad Gharibdoost; Reza Mirzaei; Katayoon Bidad; Eisa Salehi
Journal:  Immunopharmacol Immunotoxicol       Date:  2017-01-03       Impact factor: 2.730

6.  Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation.

Authors:  Joseph M Reynolds; Gustavo J Martinez; Yeonseok Chung; Chen Dong
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

7.  Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells.

Authors:  Kui Shin Voo; Laura Bover; Megan Lundell Harline; Jinsheng Weng; Naoshi Sugimoto; Yong-Jun Liu
Journal:  J Immunol       Date:  2014-06-13       Impact factor: 5.422

8.  Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis.

Authors:  D Matusevicius; P Kivisäkk; B He; N Kostulas; V Ozenci; S Fredrikson; H Link
Journal:  Mult Scler       Date:  1999-04       Impact factor: 6.312

9.  Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy.

Authors:  Javad Rasouli; Bogoljub Ciric; Jaime Imitola; Patricia Gonnella; Daniel Hwang; Kedar Mahajan; Elisabeth R Mari; Farinaz Safavi; Thomas P Leist; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

Review 10.  PAMP-DAMPs interactions mediates development and progression of multiple sclerosis.

Authors:  Norma Hernández-Pedro; Roxana Magana-Maldonado; Aleli Salazar Ramiro; Verónica Pérez-De la Cruz; Edgar Rangel-López; Julio Sotelo; Benjamin Pineda
Journal:  Front Biosci (Schol Ed)       Date:  2016-01-01
View more
  13 in total

1.  Major depression favors the expansion of Th17-like cells and decrease the proportion of CD39+Treg cell subsets in response to myelin antigen in multiple sclerosis patients.

Authors:  Priscila Mendonça do Sacramento; Marisa Sales; Taissa de Matos Kasahara; Clarice Monteiro; Hugo Oyamada; Aleida Soraia Oliveira Dias; Lana Lopes; Camilla Teixeira Castro; Átila Duque Rossi; Lucas Mattos Milioni; Anshu Agrawal; Regina Alvarenga; Claudia Cristina Vasconcelos; Cleonice Alves de Melo Bento
Journal:  Cell Mol Life Sci       Date:  2022-05-18       Impact factor: 9.261

2.  Toll-like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain.

Authors:  Andrew J Kwilasz; Suzanne M Green Fulgham; Julissa Chante Duran-Malle; Anouk E W Schrama; Eric H Mitten; Laurel S Todd; Hardik P Patel; Tracey A Larson; Madison A Clements; Kevin M Harris; Scott T Litwiler; Lewis O Harvey; Steven F Maier; Raymond A Chavez; Kenner C Rice; Anne-Marie Van Dam; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2021-01-07       Impact factor: 7.217

3.  Resolvin E1 Regulates Th17 Function and T Cell Activation.

Authors:  Fatma Oner; Carla Alvarez; Wael Yaghmoor; Danielle Stephens; Hatice Hasturk; Erhan Firatli; Alpdogan Kantarci
Journal:  Front Immunol       Date:  2021-03-17       Impact factor: 7.561

Review 4.  Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems.

Authors:  Haixia Li; Shan Liu; Jinming Han; Shengxian Li; Xiaoyan Gao; Meng Wang; Jie Zhu; Tao Jin
Journal:  Front Immunol       Date:  2021-11-01       Impact factor: 7.561

Review 5.  Emerging role of bystander T cell activation in autoimmune diseases.

Authors:  Chae-Hyeon Shim; Sookyung Cho; Young-Mi Shin; Je-Min Choi
Journal:  BMB Rep       Date:  2022-02       Impact factor: 4.778

6.  Selective serotonin reuptake inhibitor attenuates the hyperresponsiveness of TLR2+ and TLR4+ Th17/Tc17-like cells in multiple sclerosis patients with major depression.

Authors:  Marisa C Sales; Taissa M Kasahara; Priscila M Sacramento; Átila D Rossi; Marcos Octávio S D Cafasso; Hugo A A Oyamada; Joana Hygino; Fabianna Alvim; Regis M Andrade; Cláudia Cristina Vasconcelos; Cleonice A M Bento
Journal:  Immunology       Date:  2020-11-23       Impact factor: 7.397

Review 7.  Toll-like Receptor 2 in Autoimmune Inflammation.

Authors:  Kathryne E Marks; Kaylin Cho; Courtney Stickling; Joseph M Reynolds
Journal:  Immune Netw       Date:  2021-06-25       Impact factor: 6.303

Review 8.  Pattern Recognition Receptors in Multiple Sclerosis and Its Animal Models.

Authors:  M Elizabeth Deerhake; Debolina D Biswas; William E Barclay; Mari L Shinohara
Journal:  Front Immunol       Date:  2019-11-12       Impact factor: 7.561

9.  The expression profile of virus-recognizing toll-like receptors in natural killer cells of Cypriot multiple sclerosis patients.

Authors:  Elie Deeba; Anastasia Lambrianides; Marios Pantzaris; George Krashias; Christina Christodoulou
Journal:  BMC Res Notes       Date:  2020-09-29

Review 10.  Bystander CD4+ T cells: crossroads between innate and adaptive immunity.

Authors:  Hong-Gyun Lee; Min-Zi Cho; Je-Min Choi
Journal:  Exp Mol Med       Date:  2020-08-28       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.